Do Health and Forensic DNA Databases Increase Racial Disparities?
By Peter A Chow-White and Troy Duster,
PLOS Medicine
| 10. 04. 2011
In the 1990s, scientists, social advocates, policy makers, and entrepreneurs debated the promises and perils of emerging digital technologies that could bring about enormous and wide-reaching changes in society. One set of debates revolved around the Internet while the other focused on genomics. Both framed the contours of the technological and social shifts in terms of the digital divide [1]. Politicians and entrepreneurs argued that connection to the Internet would be a basic necessity for all citizens and create a better society. Policy makers were concerned that women, racial and ethnic minorities, the working class, and unemployed citizens would be left out of the network revolution if they didn't connect to the Internet. Scientists such as Walter Gilbert worried that the increase of biological information in databases from new genomic technologies would divide the world into haves and have-nots [2]. Instead of new technologies ameliorating social inequalities, many feared they would exacerbate them. In both cases of technological innovation, “access” would be the key to creating a more equitable, just, and democratic society. However, as the decade has unfolded, it...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...